Literature DB >> 10325729

Reduced bone density at completion of chemotherapy for a malignancy.

P Arikoski1, J Komulainen, P Riikonen, J S Jurvelin, R Voutilainen, H Kröger.   

Abstract

OBJECTIVES: Osteoporosis and pathological fractures occur occasionally in children with malignancies. This study was performed to determine the degree of osteopenia in children with a malignancy at completion of chemotherapy.
METHODS: Lumbar spine (L2-L4) bone mineral density (BMD; g/cm2) and femoral neck BMD were measured by dual energy x ray absorptiometry in 22 children with acute lymphoblastic leukaemia (ALL), and in 26 children with other malignancies. Apparent volumetric density was calculated to minimise the effect of bone size on BMD. Results were compared with those of 113 healthy controls and expressed as age and sex standardised mean Z scores.
RESULTS: Patients with ALL had significantly reduced lumbar volumetric (-0.77) and femoral areal and volumetric BMDs (-1.02 and -0.98, respectively). In patients with other malignancies, femoral areal and apparent volumetric BMDs were significantly decreased (-0.70 and -0.78, respectively).
CONCLUSIONS: The results demonstrate that children with a malignancy are at risk of developing osteopenia. A follow up of BMD after the completion of chemotherapy should facilitate the identification of patients who might be left with impaired development of peak bone mass, and who require specific interventions to prevent any further decrease in their skeletal mass and to preserve their BMD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325729      PMCID: PMC1717834          DOI: 10.1136/adc.80.2.143

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  39 in total

Review 1.  Steroid osteoporosis.

Authors:  I R Reid
Journal:  Calcif Tissue Int       Date:  1989-08       Impact factor: 4.333

Review 2.  Endocrine consequences of treatment of malignant disease.

Authors:  S M Shalet
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

3.  Corticosteroids and osteoporosis.

Authors:  A G Need
Journal:  Aust N Z J Med       Date:  1987-04

4.  Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment.

Authors:  B Lund; T L Storm; B Lund; F Melsen; L Mosekilde; R B Andersen; C Egmose; O H Sørensen
Journal:  Clin Rheumatol       Date:  1985-06       Impact factor: 2.980

5.  Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels.

Authors:  E F Eriksen; S F Hodgson; R Eastell; S L Cedel; W M O'Fallon; B L Riggs
Journal:  J Bone Miner Res       Date:  1990-04       Impact factor: 6.741

6.  Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukemia.

Authors:  J M Halton; S A Atkinson; L Fraher; C E Webber; W P Cockshott; C Tam; R D Barr
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

7.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.

Authors:  G Bacci; P Picci; P Ruggieri; M Mercuri; M Avella; R Capanna; A Brach Del Prever; A Mancini; F Gherlinzoni; G Padovani
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

8.  Bone mineralization after treatment of growth hormone deficiency in survivors of childhood malignancy.

Authors:  S S Nussey; S L Hyer; M Brada; A D Leiper; M Pazianas
Journal:  Acta Paediatr Suppl       Date:  1994-04

9.  Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.

Authors:  A Reiter; M Schrappe; R Parwaresch; G Henze; S Müller-Weihrich; S Sauter; K W Sykora; W D Ludwig; H Gadner; H Riehm
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

10.  ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.

Authors:  S P Hunger; M P Link; S S Donaldson
Journal:  J Clin Oncol       Date:  1994-10       Impact factor: 44.544

View more
  7 in total

1.  The impact of corticosteroids on growth and bone health.

Authors:  T Mushtaq; S F Ahmed
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

2.  Predictors of bone loss in childhood hematologic malignancies: a prospective study.

Authors:  Ghada El-Hajj Fuleihan; S Muwakkit; A Arabi; L E-O Daouk; T Ghalayini; J Chaiban; M Abboud
Journal:  Osteoporos Int       Date:  2011-04-08       Impact factor: 4.507

Review 3.  Renal function following hematological stem cell transplantation in childhood.

Authors:  Ludwig Patzer; Karim Kentouche; Felix Ringelmann; Joachim Misselwitz
Journal:  Pediatr Nephrol       Date:  2003-04-29       Impact factor: 3.714

4.  Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients.

Authors:  Carsten Müller; Corinna C Winter; Dieter Rosenbaum; Joachim Boos; Georg Gosheger; Jendrik Hardes; Volker Vieth
Journal:  BMC Musculoskelet Disord       Date:  2010-12-29       Impact factor: 2.362

5.  Avoiding the under-diagnosis of low bone mineral density in Egyptian children with chronic medical conditions affecting bone health.

Authors:  Nagwa Abdallah Ismail
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

6.  Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice.

Authors:  Emma Eriksson; Farasat Zaman; Dionisios Chrysis; Henrik Wehtje; Terhi J Heino; Lars Sävendahl
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Vitamin D and Bone Minerals Status in the Long-term Survivors of Childhood Acute Lymphoblastic Leukemia.

Authors:  Nahid Reisi; Parisa Iravani; Pouran Raeissi; Roya Kelishadi
Journal:  Int J Prev Med       Date:  2015-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.